RT Journal Article SR Electronic T1 The clinical spectrum of encephalitis in COVID-19 disease: the ENCOVID multicentre study JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.06.19.20133991 DO 10.1101/2020.06.19.20133991 A1 Pilotto, Andrea A1 Masciocchi, Stefano A1 Volonghi, Irene A1 del Zotto, Elisabetta A1 Magni, Eugenio A1 De Giuli, Valeria A1 Caprioli, Francesca A1 Rifino, Nicola A1 Sessa, Maria A1 Gennuso, Michele A1 Cotelli, Maria Sofia A1 Turla, Marinella A1 Balducci, Ubaldo A1 Mariotto, Sara A1 Ferrari, Sergio A1 Ciccone, Alfonso A1 Fiacco, Fabrizio A1 Imarisio, Alberto A1 Risi, Barbara A1 Benussi, Alberto A1 Premi, Enrico A1 FocĂ , Emanuele A1 Caccuri, Francesca A1 Leonardi, Matilde A1 Gasparotti, Roberto A1 Castelli, Francesco A1 Zanusso, Gianluigi A1 Pezzini, Alessandro A1 Padovani, Alessandro A1 on behalf of ENCOVID Study Group# YR 2020 UL http://medrxiv.org/content/early/2020/06/20/2020.06.19.20133991.abstract AB Importance Several preclinical and clinical investigations have argued for nervous system involvement in SARS-CoV-2 infection. Some sparse case reports have described various forms of encephalitis in COVID-19 disease, but very few data have focused on clinical presentations, clinical course, response to treatment and outcomes yet.Objective to describe the clinical phenotype, laboratory and neuroimaging findings of encephalitis associated with SARS-CoV-2 infection, their relationship with respiratory function and inflammatory parameters and their clinical course and response to treatment.Design The ENCOVID multicentre study was carried out in 13 centres in northern Italy between February 20th and May 31st, 2020. Only patients with altered mental status and at least two supportive criteria for encephalitis with full infectious screening, CSF, EEG, MRI data and a confirmed diagnosis of SARS-CoV-2 infection were included. Clinical presentation and laboratory markers, severity of COVID-19 disease, response to treatment and outcomes were recorded.Results Out of 45 cases screened, twenty-five cases of encephalitis positive for SARS-CoV-2 infection with full available data were included. The most common symptoms at onset were delirium (68%), aphasia/dysarthria (24%) and seizures (24%). CSF showed hyperproteinorrachia and/or pleocytosis in 68% of cases whereas SARS-CoV-2 RNA by RT-PCR resulted negative. Based on MRI, cases were classified as ADEM (n=3), limbic encephalitis (LE, n=2), encephalitis with normal imaging (n=13) and encephalitis with MRI alterations (n=7). ADEM and LE cases showed a delayed onset compared to the other encephalitis (p=0.001) and were associated with previous more severe COVID-19 respiratory involvement. Patients with MRI alterations exhibited worse response to treatment and final outcomes compared to other encephalitis.Conclusions and relevance We found a wide clinical spectrum of encephalitis associated with COVID19 infection, underlying different pathophysiological mechanisms. Response to treatment and final outcome strongly depended on specific CNS-manifestations.Question what are the phenotypes of encephalitis associated to SARS-CoV-2 infection?Findings 25 cases of encephalitis in SARS-CoV-2 infection were included in a prospective observational multi-centre study. Encephalitis cases in COVID-19 exhibited a wide heterogeneity in terms of clinical features, CSF, MRI findings, response to treatment and outcomes with 13 cases with normal MRI, 7 with heterogeneous MRI alterations and rarer ADEM/limbic encephalitis cases.Meaning heterogeneity of presentation, response to treatment and outcomes of encephalitis of COVID-19 underlines different pathophysiological mechanismsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe study was not funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Neurology Unit, Department of Clinical and Experimental Sciences University of BresciaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available from the author upon reasonable request